Company Name: Seattle Genetics, Inc.
Seattle Genetics, Inc. is a biotechnology company. The company is engaged in the development and commercialization of antibody-based therapies designed to treat cancer. The company’s antibody-drug conjugate (ADC) technology is designed to allow cell killing agents to be delivered directly to cancer cells. ADCETRIS®, the company’s lead product, is approved in over 50 countries.
Ticker Symbol: SGEN (NASDAQ)
Company Website: www.seattlegenetics.com
Headquarters: Bothell, WA